Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099713 | 0.90 | NPC1 (0.52) | NPC1ALOX5CYP3A4PTPN2PTPN1 | |
| SCHEMBL5708183 | 0.90 | NPC1 (0.52) | NPC1ALOX5CYP3A4PTPN2PTPN1 | |
| SCHEMBL4657758 | 0.84 | NPC1 (0.48) | NPC1ALOX5CYP3A4PTPN2PTPN1 | |
| SCHEMBL5102101 | 0.83 | NPC1 (0.53) | NPC1ALOX5CYP3A4PTPN2PTPN1 | |
| SCHEMBL5108117 | 0.83 | GAA (0.53) | NPC1POLBSMN1; SMN2MAPTHTT | |
| SCHEMBL5098512 | 0.83 | CYP3A4 (0.57) | NPC1ALOX5CYP3A4PTPN2PTPN1 | |
| SCHEMBL5095192 | 0.83 | NPC1 (0.44) | NPC1ALOX5CYP3A4MAPT | |
| SCHEMBL2530050 | 0.82 | NPC1 (0.46) | NPC1ALOX5CYP3A4PTPN2PTPN1 | |
| SCHEMBL3266105 | 0.81 | NPC1 (0.69) | NPC1ALOX5SMN1; SMN2MAPT | |
| SCHEMBL5095212 | 0.81 | NPC1 (0.48) | NPC1ALOX5SMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342005-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2008-03-11 | — | — | US | disclosed |
| US-7041836-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2006-05-09 | — | — | US | disclosed |
| US-20050209212-A1 | Antibiotic compounds | ASTRAZENECA UK LIMITED | 2005-09-22 | — | — | US | disclosed |
| US-20030144264-A1 | Antibiotic compounds | ZENECA LIMITED | 2003-07-31 | — | — | US | disclosed |
| US-6521612-B2 | Antibiotic against grampositive, gramnegative bacteria | ZENECA LTD. (GB) | 2003-02-18 | — | — | US | disclosed |
| US-20020042408-A1 | Antibiotic compounds | ZENECA LIMITED | 2002-04-11 | — | — | US | disclosed |
| US-6187804-B1 | Antibiotic compounds | ZENECA LIMITED (GB) | 2001-02-13 | — | — | US | disclosed |
| US-5856321-A | PREPARATION OF CARBAPENEMS | ZENECA LIMITED (GB) | 1999-01-05 | — | — | US | disclosed |
| EP-0579826-B1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| CN-1036006-C | Antibiotic compounds | ZENECA LTD (GB) | 1997-10-01 | — | — | CN | disclosed |
| US-5652233-A | CARBAPENICILLINS | ZENECA LIMITED (GB) | 1997-07-29 | — | — | US | disclosed |
| US-5478820-A | Carbapenem deivatives; bactericides | ZENECA LTD. (GB) | 1995-12-26 | — | — | US | disclosed |
| EP-0579826-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1994-01-26 | — | — | EP | disclosed |
| CN-1079224-A | Antifungal compound | ZENECA LTD (GB) | 1993-12-08 | — | — | CN | disclosed |
| WO-1993015078-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209212-A1 | Antibiotic compounds | NRDC, NPR3, NGLY1 | NPC1 848/4885ALOX5 3005/4885CYP3A4 1010/4885 |
| US-20020042408-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | NPC1 144/4885ALOX5 3595/4885CYP3A4 631/4885 |
| US-20030144264-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | NPC1 156/4885ALOX5 3618/4885CYP3A4 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.